IRIS Accounts Production v24.3.0.553 07598777 Board of Directors 1.6.23 31.5.24 31.5.24 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh075987772023-05-31075987772024-05-31075987772023-06-012024-05-31075987772022-05-31075987772022-06-012023-05-31075987772023-05-3107598777ns15:EnglandWales2023-06-012024-05-3107598777ns14:PoundSterling2023-06-012024-05-3107598777ns10:Director12023-06-012024-05-3107598777ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3107598777ns10:SmallEntities2023-06-012024-05-3107598777ns10:AuditExempt-NoAccountantsReport2023-06-012024-05-3107598777ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3107598777ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3107598777ns10:FullAccounts2023-06-012024-05-3107598777ns5:CurrentFinancialInstruments2024-05-3107598777ns5:CurrentFinancialInstruments2023-05-3107598777ns5:Non-currentFinancialInstruments2024-05-3107598777ns5:Non-currentFinancialInstruments2023-05-3107598777ns5:ShareCapital2024-05-3107598777ns5:ShareCapital2023-05-3107598777ns5:RetainedEarningsAccumulatedLosses2024-05-3107598777ns5:RetainedEarningsAccumulatedLosses2023-05-3107598777ns10:RegisteredOffice2023-06-012024-05-3107598777ns5:FurnitureFittings2023-06-012024-05-3107598777ns5:MotorVehicles2023-06-012024-05-3107598777ns5:FurnitureFittings2023-05-3107598777ns5:MotorVehicles2023-05-3107598777ns5:FurnitureFittings2024-05-3107598777ns5:MotorVehicles2024-05-3107598777ns5:FurnitureFittings2023-05-3107598777ns5:MotorVehicles2023-05-3107598777ns5:WithinOneYearns5:CurrentFinancialInstruments2024-05-3107598777ns5:WithinOneYearns5:CurrentFinancialInstruments2023-05-3107598777ns5:CurrentFinancialInstruments2023-06-012024-05-310759877712023-06-012024-05-31
REGISTERED NUMBER: 07598777 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MAY 2024

FOR

CLAIDMHOR PHARMA LIMITED

CLAIDMHOR PHARMA LIMITED (REGISTERED NUMBER: 07598777)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024










Page

Statement of Financial Position 1 to 2

Notes to the Financial Statements 3 to 6


CLAIDMHOR PHARMA LIMITED (REGISTERED NUMBER: 07598777)

STATEMENT OF FINANCIAL POSITION
31 MAY 2024

31.5.24 31.5.23
Notes £    £   
FIXED ASSETS
Property, plant and equipment 4 41,201 42,291

CURRENT ASSETS
Debtors 5 211,317 69,460
Cash at bank 252,112 956,939
463,429 1,026,399
CREDITORS
Amounts falling due within one year 6 (396,189 ) (810,947 )
NET CURRENT ASSETS 67,240 215,452
TOTAL ASSETS LESS CURRENT
LIABILITIES

108,441

257,743

CREDITORS
Amounts falling due after more than one
year

7

(28,207

)

(32,538

)
NET ASSETS 80,234 225,205

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 80,134 225,105
80,234 225,205

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CLAIDMHOR PHARMA LIMITED (REGISTERED NUMBER: 07598777)

STATEMENT OF FINANCIAL POSITION - continued
31 MAY 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 February 2025 and were signed on its behalf by:





M J Dey - Director


CLAIDMHOR PHARMA LIMITED (REGISTERED NUMBER: 07598777)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024


1. STATUTORY INFORMATION

Claidmhor Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 07598777

Registered office: c/o DPC Accountants
Stone House, 55 Stone Road Business Park
Stone Road
Stoke-On-Trent
Staffordshire
ST4 6SR

The principal activity of the company during the year was that of biotechnology and pharma consultants.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Significant judgements and estimates
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

As described in the accounting policies of the financial statements, depreciation tangible fixed assets has been based on estimated useful lives and residual values deemed appropriate by the directors. Estimated useful lives and residual values are reviewed annually and revised as appropriate. Revisions take in to account actual asset lives and residual values as evidence by disposals during current and prior accounting periods.

Revenue recognition
Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

CLAIDMHOR PHARMA LIMITED (REGISTERED NUMBER: 07598777)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 15% reducing balance from date purchased
Motor vehicles - 25% reducing balance from purchase date

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses.

Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.


CLAIDMHOR PHARMA LIMITED (REGISTERED NUMBER: 07598777)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.
Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4. PROPERTY, PLANT AND EQUIPMENT
Fixtures
and Motor
fittings vehicles Totals
£    £    £   
COST
At 1 June 2023 6,480 55,224 61,704
Additions 96 41,414 41,510
Disposals - (55,224 ) (55,224 )
At 31 May 2024 6,576 41,414 47,990
DEPRECIATION
At 1 June 2023 3,795 15,618 19,413
Charge for year 406 6,054 6,460
Eliminated on disposal - (19,084 ) (19,084 )
At 31 May 2024 4,201 2,588 6,789
NET BOOK VALUE
At 31 May 2024 2,375 38,826 41,201
At 31 May 2023 2,685 39,606 42,291

CLAIDMHOR PHARMA LIMITED (REGISTERED NUMBER: 07598777)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.24 31.5.23
£    £   
Trade debtors 206,665 65,885
Amounts owed by group undertakings 1,203 -
Tax - 1,202
Prepayments 3,449 2,373
211,317 69,460

Amounts owed by group undertakings are unsecured, interest free and repayable on demand.

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.24 31.5.23
£    £   
Hire purchase contracts 8,105 6,841
Trade creditors 4,278 417
Amounts owed to group undertakings 337,841 795,109
Tax 8,158 -
VAT 31,778 2,096
Accruals and deferred income 6,029 6,484
396,189 810,947

Amounts owed to group undertakings are unsecured, interest free and repayable on demand.

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.5.24 31.5.23
£    £   
Hire purchase contracts 28,207 32,538

8. SECURED DEBTS

The following secured debts are included within creditors:

31.5.24 31.5.23
£    £   
Hire purchase contracts 36,312 39,379

The hire purchase liabilities are secured on the related assets.

9. POST BALANCE SHEET EVENTS

There were no significant events up to the date of approval of the financial statements by the Board.

10. ULTIMATE CONTROLLING PARTY

Mountain Heather Holdings Limited is the company's ultimate parent undertaking.